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ABSTRACT 
 
Misoprostol is often used for the purpose of induction of labour. However, its effect 
on fetal heart rate has not been systematically studied.  
Objective 
To assess the effect of misoprostol on fetal heart rate parameters during induction of  
labour from 38 completed weeks in women with previous intrauterine death or 
postterm pregnancy. 
Study design 
A retrospective descriptive study of 127 women for a period of 18 months. 
Method 
Women who underwent induction of labour with misoprostol for either previous 
intrauterine death or postterm pregnancy at Tygerberg hospital were eligible. 
The selected process of induction of labour happened according to the departmental 
protocol. The primary outcomes were changes in fetal heart rate (variability, 
accelerations and decelerations) pre-and post-administration of misoprostol. 
Secondary outcomes were neonatal highcare or intensive care unit (ICU) 
admissions. 
Results 
There was no statistical difference in the mean fetal heart rate and baseline 
variability in relation to time recordings after administration of misoprostol. There 
were no statistically significant differences in the distribution of accelerations and 
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decelerations in different time intervals before and after administration. There were 
more reactive patterns at all time intervals after the administration of misoprostol, but 
these differences did not quite reach statistical significance. In both study groups no 
neonatal complications or intensive care admissions were reported. 
Conclusion 
In the absence of contra indications, 50mcg of oral misoprostol can be given to 
mothers for induction of labour as no harmful fetal heart tracing abnormalities were 
found for 45 minutes; however large prospective randomized controlled trials are still 
needed to confirm effectiveness and evaluate further maternal and neonatal safety 
issues. Optimal dose and frequency also still need robust interrogation. Based on 
this thesis it does appear that misoprostol is probably not harmful to the fetus under 
these circumstances. 
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ABSTRAK 
Misoprostol word dikwels gebruik vir induksie van kraam.  Die effek daarvan op 
fetale hartspoed is egter nie sistematies ondersoek nie. 
Doel 
Om die effek van misoprostol op fetale hartspoedparameters gedurende die induksie 
van kraam van 38 voltooide weke in vroue met vorige intra-uteriene dood or oortyd 
swangerskap te evalueer. 
Studei-ontwerp 
„n Retrospektiewe beskrywende studie van 127 vroue oor „n periode van 18 maande. 
Metode 
Vroue wat induksie van kraam met misoprostol ondergaan het vir of vorige intra-
uteriene dood of oortyd swangerskap by Tygerberg Hospitaal is ingesluit.   
Die proses van induksie van kraam is volgens departementele protokol uitgevoer.  
Die primêre uitkomste was veranderinge in fetale hartspoed (variasie, versnellings 
en verstadigings) pre- en post-toediening van misoprostol.  Neonatale hoësorg of 
intensiewe sorg toelatings was sekondêre uitkomste. 
Resultate 
Ons het geen statistiese verskille in gemiddelde fetale hartspoed en basislynvariasie 
in verhouding tot die tyd na toediening van misoprostol gevind nie.  Daar was geen 
statisties betekenisvolle verskille in die verspreiding van versnellings en 
verstadigings in verskillende tydsintervalle nie.  Daar was meer reaktiewe patrone 
gedurende alle tydsintervalle na die toediening van misoprostol, maar hierdie 
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verskille was nie statisties betekenisvol nie.  In beide studiegroepe was daar geen 
neonatale komplikasies of intensiewe sorg toelatings nie. 
Gevolgtrekking 
In die afwesigheid van kontra-indikasies kan 50 mcg misoprostol aan moeders 
toegedien word vir induksie van kraam aangesien geen skadelike fetale hartsped 
abnormaliteite gevind is nie.  Groot prospektiewe gerandomiseerde gekontroleerde 
studies word steeds benodig om effektiwiteit te bevestig en om moederlike en fetale 
veiligheidskwessies verder te evalueer.  Optimale dosis en frekwensie benodig ook 
robuuste ondersoek.  Gebaseer op hierdie tesis kom dit voor of misoprostol 
waarskynlik nie skadelik vir die fetus onder hierdie omstandighede nie. 
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INTRODUCTION 
 
Induction of labour is a common intervention, performed for medical, obstetric or 
social indications. (1,2).  More than 22% of all gravid women undergo induction of 
labour in the United States, where the incidence of induction of labour has more than 
doubled since 1990 to 225 per 1000 live births in 2006. (3)  Corresponding figures 
for South Africa are not available.  
 
Cervical ripening is the first component of labour induction.  If the cervix is not 
sufficiently dilated, then drugs or mechanical cervical dilators should be used to ripen 
the cervix before labour is induced.  Common medical and obstetric indications 
include post-term pregnancy, pre-labour rupture of membranes, hypertensive 
disorders and diabetes mellitus. (2)  Various methods of induction of labour have 
been described.  The approach in individual patient depends on the indication for 
induction of labour, the ripeness of the cervix and whether the membranes have 
ruptured.  Prostaglandins are used to ripen the cervix in women with unfavourable 
cervical scores where the membranes cannot be ruptured. 
 
Misoprostol is a synthetic prostaglandin analogue which is commonly used for 
induction of labour in various hospitals in the Western Cape including Tygerberg 
Hospital.  It is cheap and heat stable.  It both ripens the cervix and induces labour.  
Oral use of misoprostol may be convenient, but high doses could cause uterine 
hyperstimulation and uterine rupture which may be life threatening for both mother 
and fetus. When used in low doses oral misoprostol is as effective as vaginal 
dinoprostone, with no increased hyperstimulation. (4) 
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If misoprostol is used orally the dose should not exceed 50mcg.  This dose can be 
repeated every four hours for a total of six doses; this is therefore the protocol we 
follow at Tygerberg hospital.   
 
It is likely that misoprostol will continue to be used for many more years to come and 
therefore warrants investigation to its effect to fetal heart rate parameters using 
National Institute for Clinical Excellence Guidelines (NICE) classification.  This will be 
applied to the commonly induced group of women at Tygerberg hospital for example 
(e.g.) post-term and previous intrauterine deaths who are 38 weeks gestation and 
above with a live fetus in the index pregnancy. 
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LITERATURE REVIEW 
 
Using the Medline database, an electronic search was done on the subject of effect 
of misoprostol on fetal heart rate parameters. 
Articles were identified using the keywords “misoprostol” AND “fetal heart rate 
parameters”. 
The Med database, Up to date and Cochrane library were also searched. 
 
INTRODUCTION 
 
For a successful induction of labour, adequate uterine contractions and progressive 
dilatation of the uterine cervix is needed.  This realization has therefore led to 
evolution of various methods used to ripen the cervix (e.g. Prostaglandins) and 
predict a possible outcome of the induction.  
  
ASSESSMENT OF THE CERVIX 
 
The cervix is a dynamic structure which undergoes many changes more pronounced 
during the late third trimester. (5)  There are biochemical changes in the 
proteoglycan matrix and collagen degradation. There is a marked increase in 
vascularity, accumulation of interstitial fluid and migration of white cells into the 
cervical tissue. (5)  These changes lead to alteration in bio-physical characteristics of 
the cervix in that they cause increased compliance and less resistance to dilatation.   
 
Several cervical scoring systems have been proposed in an attempt to establish 
guidelines for cervical assessment, so as to predict the chances of a successful 
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induction.  The most widely accepted of these various scores is the one proposed by 
Bishop in 1964, (6) who suggests assessment of five different characteristics: 
 
(i) Level of descent of the presenting part 
(ii) Cervical length 
(iii) Cervical dilatation 
(iv) Cervical consistency 
(v) Position of the cervix relative to the axis of the pelvis.  
 
HISTORICAL PERSPECTIVES 
 
Before 20th century 
 
Early literature records date to the 1500‟s, with a mixture of juniper berries, 
cinnamon and castor oil recommended to expedite birth. (7) 
 
The medical history of labour induction really starts in the 18th century. Maculey in 
1756 induced labour before term so as to avoid the hazards of both caesarean 
section and fetal extraction with a crochet. (8) 
 
AFTER 20TH CENTURY 
 
A new approach and the modern era of induction of labour began in 1928 with the 
introduction of purified posterior pituitary extract which later became established in 
1955 when synthetically prepared oxytocin was made available commercially. (9) 
While the initial oxytocin preparation were crude and unreliable in effect, 
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development of syntocinon allowed intravenous titration to produce a more 
predictable and effective method of induction of labour, but by 1968 a rival in the 
form of prostaglandins had emerged for induction of labour. (10, 11) 
 
This all happened after Karim in 1971 reported success with intravenous F2 alpha 
and prostaglandins E2 and they now have been widely used for induction of labour 
ever since. 
 
Prostaglandins represent an excellent option for induction in women who because of 
unfavourable cervix with intact membranes are poor candidates for induction using 
oxytocin. To date the commercial availability of stable preparation e.g. 
Prostaglandins E2 and prostaglandins E1 (tablets) has increased the clinical use of 
prostaglandins for priming of the cervix and increase chances of vaginal delivery 
reducing the risk of caesarean section. 
 
PROSTAGLANDINS 
 
Their existence was established through observation by Kurzork and Lieb in 1930, 
who noticed the ability of human semen to initiate uterine contractions. (12)  Von 
Euler isolated substances from male prostate that were shown to initiate contractions 
of the uterus and named them prostaglandins. (13)  Bergstroom and Sjovall isolated 
the first prostaglandins (PGF1 alpha in 1957 and in 1964), (14,15) and this led to 
biosynthesis of several uterotonic prostaglandins. 
Prostaglandins consist of 20 carbon fatty acid molecules derived from dietary fatty 
acid, and consist of a pentane ring attached to 2 adjacent carbons. (16,17,18)   
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Prostaglandins are classified into six groups (A to F), based on the structure or 
substitution of a pentane ring.  The sub-script numerical (1,2,3) indicates the number 
of double bonds in the fatty acid back bone. (16,17,19). 
 
Prostaglandins E1 has a trans double bond between C13 and C14 while 
prostaglandins E2 has an additional CIS double bond at the C5 C6 position (20,17) 
 
MISOPROSTOL 
 
It is a synthetic prostaglandin related to prostaglandin E1. 
Figure (1) Development of misoprostol from prostaglandin E1 (Collins 1985) 
 
  Prostaglandin E1     Misoprostol 
Prostaglandin E1 is an effective inhibitor of gastric acid secretion when administered 
intravenously. However there are a number of disadvantages when it is used in the 
treatment of peptic ulcer disease namely the(lack of oral activity, short duration of 
action and side effects e.g. nausea and vomiting, diarrhoea, trembling ). (20) 
Misoprostol was then developed to manipulate prostaglandin E1 to produce an orally 
active compound whilst minimizing side effects.   
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TOXICITY AND TERATOGENICITY 
 
Pre-clinical trials evaluating the toxicity of misoprostol were performed in rats, mice 
and dogs in which most clinical sequalae were observed (diarrhoea, emesis, tremor, 
reduced motor activity). (15)  The studies done indicate a safety margin of 500 to 
1000 fold between the lethal doses observed in animals and therapeutic doses 
administered to humans.   Carcinogenic and fertility properties were also studied in 
rats, mice and rabbits without demonstrable effects attributable to misoprostol. (15) 
In conclusion misoprostol showed no evidence of embryo toxicity, fetotoxicity or 
teratogenicity. (15) 
 
MISOPROSTOL FOR INDUCTION OF LABOUR 
 
INTRODUCTION 
 
Misoprostol is licenced for use in the treatment of gastric ulcers. Despite this it has 
and continues to be used off code in obstetric and gynaecology practice for first and 
second trimester terminations of pregnancy, (21) and in the third trimester of 
pregnancy for intrauterine deaths. (22)  More recently misoprostol has been used for 
induction of labour at term in the presence of a viable fetus, with both vaginal 
(Hofmeyr 2005b) and oral (Alfirevic 2005) routes of administration being used.   
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SAFETY OF MISOPROSTOL 
 
Misoprostol and uterine rupture 
 
There have been several case reports of uterine rupture and its possible adverse 
outcomes when used as an induction agent (maternal or fetal death). (23,24,25,26)  
These were women with scarred and unscarred uteri after administration of either 
oral or vaginal misoprostol in the presence of a live fetus or intra-uterine death.  
Doses varied from 25mcg (23,24,26) up to 600mcg in cases of fetal demise. (25)  
Attempts have since been made to address safety of misoprostol use in a previously 
scarred uterus with Sciscione (1998) and Wing (1998) initiating randomised 
controlled trials. 
 
Sciscione compared 50mcg intra-vaginal misoprostol at four hourly intervals with 
intra-cervical Foleys catheter (women with previous caesarean birth were not 
excluded).  One woman with a scarred uterus suffered rupture following misoprostol 
but the results are inconclusive as it was not clear as to how many women with 
scarred uteri were involved.  
 
Wing and colleagues randomised women with a  previous caesarean birth where 17 
women received 25mcg vaginal misoprostol at six hourly intervals and 21 women 
received oxytocin.  Two women in the misoprostol group were diagnosed with scar 
disruption and due to the safety concerns of misoprostol in that environment, the trial 
was terminated prematurely.  It is therefore not possible to advise on the safety of 
misoprostol in women with previous caesarean births until further studies emerge.   
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Misoprostol and Meconium stained liquor 
 
This concern was raised as to whether the use of misoprostol leads to meconium 
stained liquor during induction of labour. (27)  Postulation by Matonhodze (2002) 
was that in vitro animal studies indicate the stimulation of ileal smooth muscle by 
both dinoprostone and misoprostol.  However the systematic reviews of both vaginal 
(Hofmeyr 2005b) and oral (Alfirevic 2005) routes provide re-assurance about the 
safety of misoprostol with regards to the presence of meconium stained liquor.   
 
COCHRANE REVIEW 
 
Oral misoprostol for induction of labour 
 
Thirteen Randomised controlled trials (Alfirevic 2005) in which oral misoprostol was 
compared to prostaglandin E2, oxytocin, vaginal misoprostol and placebo, but only 
four were double blinded placebo controlled.   
 One was misoprostol and prostaglandin E2. (28)  The last two comparing oral with 
vaginal misoprostol. (29, 26) 
 
Two trials were identified where oral misoprostol was compared with intravenous 
oxytocin. Women were allocated as follows, 50mcg at four hourly intervals,(30) and 
100mcg four hourly. (31)  Meta-analysis results of the two trials showed no 
difference in two outcomes; caesarean births (188 patients, Relative Risk (RR) 0.97, 
95% Confidence Interval (CI) 0.43 – 2.22) and uterine hyperstimulation with fetal 
heart rate changes (188 patients, RR 0.96, 95% CI 0.25 – 3.66). 
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Oral misoprostol versus vaginal prostaglandin E2 
 
Two trials were identified involving 962 women. Women were given vaginal 
prostaglandin E2 or 50mcg oral misoprostol both six hourly to a maximum of four 
doses in a 24 hour cycle. (28) Random distribution vaginal prostaglandin E2 or 
titrated oral misoprostol solution starting at 20mcg increasing to 40mcg if no clinical 
effect was observed. (32) 
 
Meta-analysis results of the two trials showed no difference in caesarean births (959 
patients, RR 0.9, 95% CI 0.70 -1.17),uterine hyperstimulation with associated fetal 
heart rate changes (929 patients, RR 0.87, 95% CI 0.49 -1.56) and failure to achieve 
vaginal birth  within the first 24 hours of induction of labour (691 patients, RR 1.19, 
95% CI 0.94 – 1.51). 
 
Oral misoprostol versus oral misoprostol 
 
A meta-analysis showed that women receiving oral misoprostol in doses ranging 
from 50mcg four hourly to 100mg three hourly and 200mcg six hourly were more 
likely not to deliver within the first 24 hours. The four trials included 877 patients (RR 
1.27, 95% CI 1.09 – 1.47).   
 
If one looks at other outcomes oral misoprostol was associated with fewer caesarean 
births. This was confirmed in 7 trials that included 1276 patients (RR 0.77, 95% CI 
0.61 – 0.97), and no differences were observed in uterine hyperstimulation and route 
of administration in 6 trials that included 1236 patients (RR 1.1, 95% CI 0.78 – 1.47). 
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UTERINE HYPERSTIMULATION 
 
This is a well-recognised possible complication after induction of labour with 
prostaglandins and this can hamper utero placental perfusion which can ultimately 
present as fetal heart rate abnormalities.  Uterine hyperstimulation is well 
documented and described following misoprostol induction of labour. (33, 34) 
It is more pronounced with the use of vaginal misoprostol compared to oxytocin and 
vaginal prostaglandin E2. (34) 
 
In trying to determine any effect of dose on the occurrence of hyperstimulation, lower 
dosing regimens defined as 25mcg or less at four hourly or less intervals have been 
compared with higher dosing regimens. (34) 
 
Women who received lower doses of misoprostol were less prone to experience 
uterine hyperstimulation with fetal heart rate abnormalities (RR 0.50, 95% CI 0.36 – 
0.71). There were also trends towards fewer infants with Apgar scores of <7 at five 
minutes (RR 0.76, 95% CI 0.40 – 1.45), and fewer neonatal ICU admissions (RR 
0.82, 95% CI 0.64 – 1.05). 
 
RATIONALE FOR STUDYING MISOPROSTOL 
 
Although other agents are available in our hospital for pre-labour cervical ripening 
e.g. vaginal prostaglandin E2 and titrated doses of oxytocin for those with ruptured 
membranes and have been found to be safe and effective, however there are short- 
comings with their use.   
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Vaginal prostaglandin E2 for example is administered six hourly with multiple pelvic 
examinations by different care providers including high costs of the drug compared 
to misoprostol tablets. 
 
We therefore assessed the effect of the current oral dosage (50mcg) of misoprostol 
as an induction agent on the fetal heart rate parameters using the NICE 
classification. The lack of information on the effect of misoprostol on fetal heart rate 
parameters further encouraged the study. 
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MATERIALS AND METHODS 
We performed a retrospective descriptive study of all women who underwent 
induction of labour with misoprostol for either previous intrauterine death or postterm 
pregnancy at Tygerberg Hospital over an 18 month period.  Names of women were 
identified from the antenatal ward register.  We accepted the managing physicians 
indication for induction of labour as indicated in the patient notes.   
The process of induction of labour happened according to a departmental protocol.  
Once the indication for induction of labour had been confirmed, clinicians ensured 
that no contra-indication to vaginal delivery existed.  A vaginal examination was 
subsequently done to determine the Bishop score and to ascertain whether cervical 
ripeness was sufficient to rupture membranes.  If not, misoprostol was used to 
improve the Bishop score to facilitate rupture of membranes at a later stage.  The 
administration of misoprostol took place in the antenatal ward.  
A cardiotocograph was performed for 15 minutes prior to the administrationof 
misoprostol.  If the cardiotocograph showed a normal heart rate, variability above 5 
beats per minute (BPM) and the absence of decelerations of the fetal heart rate 
(FHR), the patient took the first dosage of 50 micrograms misoprostol per os.  The 
FHR was then monitored for another 45 minutes.  A photostat was made of this 
record of the first cardiotocograph (approximately 60 minutes).  
 All identifications, as well as the note indicating the time of misoprostol 
administration were removed from photocopies. The photocopy was then cut into five 
windows of ten minutes each representing the following five periods:  The last 10 
minutes before taking the dosage, the first ten minutes after taking the medication, 
minutes ten to 20 after taking the medication, minutes 20 to 30 after taking the 
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medication and minutes 30 to 40 after taking the medication.  These five copies were 
then numbered according to a list of computer generated numbers in blocks of 100.  
This meant that the assessor (Prof DW Steyn) assessed each individual ten minute 
strip without knowing which patient‟s record he was looking at or whether the strip 
was recorded before or after the medication was taken.   
Assessment of each ten minute window was done according to the proposal of the 
National Institute for Clinical Excellence (NICE).  In essence, each of the baseline 
fetal heart rate, fetal heart rate variability and decelerations were identified as 
reassuring, non-reassuring or abnormal.  The presence of accelerations was 
considered to be reassuring.  (See table).   
 
 
Adapted from NICE fetal monitering guidelines, May 2001 
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The primary outcomes were: 
1. Changes in fetal heart rate, fetal heart rate variability, accelerations and 
decelerations of the fetal heart rate pre- and post administration of misoprostol. 
The secondary outcomes were: 
1. Neonatal highcare or Intensive Care Unit (ICU) admissions. 
The data was analysed using the SPSS software (Statistical Package for Social 
Science). Discrete data was compared by calculating relative risks with 95% 
confidence limits, as well as the chi2 test.  Fisher‟s exact test was used to compare 
ratios where the expected value in any cell of a two-by-two table was less than five.  
The means of normally distributed continuous data was compared by analysis of 
variance, while the medians of continuous data which are not distributed normally, 
were calculated using the non-parametric Mann Whitney u test.  A p-value of < 0.05 
was considered to be statistically significant, where applicable.   
ETHIC APPROVAL 
 
The project was registered with the Health Research and Ethics Committee (HREC) 
of the Health Sciences of Stellenbosch University. Ethics Approval with a waiver of 
consent was obtained N11/08/248. 
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RESULTS 
We included data from 127 women who were admitted for induction of labour for 
either postterm pregnancy or a previous intrauterine death over an 18 month period.  
Seventy-five women had a previous intrauterine death as an indication for induction 
of labour, while postterm pregnancy was an indication in 52 cases.  We analyzed 
data from the first cardiotocograph recorded immediately before and till forty minutes 
after the first administration of misoprostol, irrespective of how many courses the 
individual patients received.  There were no deliveries, specifically for fetal distress, 
during the course of this first administration of misoprostol. 
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The demographic data of participants are shown in table 1. 
 
 
Previous IUD (n = 
75) 
Postterm (n = 52) 
p-value 
Age (years) 28.99 ± 5.3 28.31 ± 6.4 0.517 
Gestational age at 
delivery (weeks) 
38.03 ± 0.16 41.87 ± 1.10 0.000 
Weight (kg) 86.21 ± 17.96 84.73 ± 18.89 0.655 
Length (cm) 158.36 ± 7.20 158.96 ± 7.00 0.640 
BMI (kg/m3) 34.01 ± 6.17 33.17 ± 6.70 0.466 
RPR positive 0 0 NA 
HIV positive 5 8 0.10 
Rh-positive 75 50 0.17 
Smoker 28 14 0.15 
Gravidity 2 (1-5) 2 (1-5) 0.009 
Parity 2(1-4) 1(0-4) 0.003 
Other complications 
during previous 
pregnancy 
29 (38.7%) 14 (26.9%) 0.24 
 
Table 1:  The demographic data of participants 
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The nature of the complications during the previous pregnancy is summarized in 
Table 2. 
 Previous IUD (n = 
75) 
Postterm (n = 52) 
Acute 
Pyelonephritis 
0 1 
Asthma 2 2 
Cardiovascular 
System 
0 1 
Diabetes Mellitus 6 0 
Epilepsy 1 1 
HIV 1 4 
Hypertension 14 2 
Hypothyroidism 1 1 
Preterm Labour 2 1 
 
Table 2:  Complications which required attention during previous pregnancies 
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There were no previous IUD‟s in women who underwent induction of labour for 
postterm pregnancy, although two of these women had previous miscarriages.  The 
related conditions at time of the previous IUD are summarized in Table 3. 
 
Gestational age at time of previous loss 
 
<28w 
28 – 
33w 
34 - 
37 
>37
w 
Unknown 
gestation 
TOTAL 
Unknown cause 0 6 3 13 4 26 
Abruptio placentae 0 5 8 1 0 14 
Placental 
insufficiency 
0 
7 
3 1 3 14 
Chorioamnionitis 2 8 1 1 1 13 
Congenital 
abnormalities 
0 2 1 0 1 4 
Cord prolapse 0 0 1 0 0 1 
Other causes 1 2 0 0 0 3 
 
Table 3:  Details of the previous IUD‟s.  The right part of the table indicates the 
gestational age at which the previous loss occurred. 
 
  
Stellenbosch University  http://scholar.sun.ac.za
20 
 
Twenty-one women underwent caesarean section. (Table 4).  While fetal distress 
occurred more commonly in women with a history of previous IUD, this difference 
was not statistically significantly different. 
 Previous IUD (n = 
75) 
Postterm (n = 
52) 
Vaginal delivery 62 44 
Caesarean section for cephalo-pelvic 
disproportion 
5 7 
Caesarean section for fetal distress 8 1 
 
Table 4:  Route of delivery according to indication for induction of labour. 
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There were no clinically significant problems as far as antenatal fetal assessment 
was concerned. (Table 5). 
 
 Previous IUD (n = 
75) 
Postterm (n = 
52) 
p-value 
Umbilical artery Doppler    
 None 12 45  
 Below 75th Centile 6 0  
 75th – 95th Centile 57 7 0.000 
Abnormal SF-growth 0 0 -- 
Any other antenatal 
complications 
0 0 -- 
Early ultrasound done 75 37 0.000 
 
Table 5: Antenatal observations and investigations related to fetal well-being. 
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The perinatal outcome is summarized in Table 6.  Seventy percent of babies were 
male. 
 
 Previous IUD (n = 
75) 
Postterm (n = 
52) 
p-value 
Birth weight < 2500g 7 8 0.22 
Neonatal complications 0 0 -- 
Neonatal intensive care 
admission 
0 0 -- 
Mean birth weight (g) 3142.7 ± 468.3 3092.4 ± 535.3 0.58 
Gestational age (w) 38.03 ± 0.16 41.87 ± 1.10 0.000 
Table 6:  The perinatal outcome in the two study groups 
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The distribution of fetal heart rate characteristics is depicted in table 7.   
 
 Mean / 
Median 
25th 
Centile 
50th 
Centile 
75th 
Centile 
Fetal heart rate (bpm) 134.52 ± 
9.02 
127.50 133.50 141.00 
Accelerations (per 10 min) 2 (0 – 12) 0 2 4 
Early Decelerations (per 10 min) 0 (0 – 2) 0 0 0 
Variable Decelerations (per 10 
min) 
0 (0 – 5) 
0 0 1 
Atypical Variable Decelerations 
(per 10 min) 
0 (0 – 4) 0 0 0 
Late Decelerations  (per 10 min) 0 (0 – 3) 0 0 0 
 
Table 7:  A summary of the major findings of the 635 cardiotocographs included in 
the study. 
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The mean fetal heart rate and the mean fetal heart rate baseline variability for all 
cardiotocographs are shown in figure 1 and figure 2 respectively. 
120
125
130
135
140
145
150
-10 0 10 20 30
Time since administration of misoprostol (min)
Mean fetal heart rate  (bpm) in relation to the 
administration of misoprostol
 
Figure 1:  The mean fetal heart rate for all recordings. 
 
 
5
10
15
-10 0 10 20 30
Time since administration of misoprostol (min)
Mean fetal heart rate baseline variability  (bpm) in 
relation to the administration of misoprostol
 
 
Figure 2:  The mean fetal heart rate baseline variability for all recordings. 
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The distribution of accelerations and decelerations in the different time intervals is 
shown in table 8.  There were no statistically significant differences between any of 
the related groups. 
 -10 0 10 20 30 
Accelerations (per 10 min) 2 
(0;3.75) 
2 (1;4) 2 (1;4) 2 (0;4) 2 (1;4) 
Early Decelerations (per 10 min) 0 (0;0) 0 (0;0) 0 (0;0) 0 (0;0) 0 (0;0) 
Variable Decelerations (per 10 
min) 
0 (0;1) 0 (0;0) 0 (0;0) 0 (0;0) 0 (0;0) 
Atypical Variable Decelerations 
(per 10 min) 
0 (0;0) 0 (0;0) 0 (0;0) 0 (0;0) 0 (0;0) 
Late Decelerations  (per 10 min) 0 (0;0) 0 (0;0) 0 (0;0) 0 (0;0) 0 (0;0) 
Variability (bpm) 11.2 ± 
3.2 
11.4 
±3.2 
11.3 
±3.0 
11.1 
±3.1 
11.1 
±3.0 
Table 8:  Changes in accelerations and decelerations of the fetal heart rate in 
relation to the timing of the administration of misoprostol (median (25th 
centile;75th centile). 
 
Table 9 contains data about the distribution of fetal heart rate and fetal heart rate 
variability at the different time intervals for each of the two groups.  There were no 
statistically significant differences between the values of any time interval compared 
with any other time interval for any of the two groups.      
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 INDICATION FOR INDUCTION OF LABOUR 
 Previous IUD  Postterm pregnancy 
TIMIN
G 
-10 0 10 20 30  -10 0 10 20 30 
FHR 
(bpm) 
135.
13 ± 
9.12 
133.
76 ± 
9.09 
134.
19 ± 
8.98 
133.1
9 ± 
9.44 
134.
41 ± 
9.98 
 133.
5 ± 
8.9 
135.
54 ± 
8.59 
136.
69 ± 
8.84 
134.
67 ± 
8.30 
134.
86 ± 
8.35 
 25th 
Cen
tile 
127.
50 
127.
25 
127.
00 
127.5
0 
127.
50 
 127.
50 
129.
00 
131.
00 
127.
50 
127.
50 
 75th 
Cen
tile 
141.
00 
141.
00 
141.
00 
137.2
5 
141.
00 
 139.
00 
143.
50 
141.
00 
141.
00 
139.
00 
Baselin
e 
Variabil
ity 
(bpm) 
11.2
6 
±3.4
0 
11.3
7 ± 
2.82 
11.5
1 ± 
2.80 
11.19 
± 
3.56 
11.1
9 ± 
2.95 
 11.1
2 ± 
2.94 
11.4
7 ± 
3.75 
11.1
2 ± 
3.32 
10.9
2 ± 
2.49 
10.8
6 ± 
3.06 
 25th 
Cen
tile 
8.00 10.0
0 
10.0
0 
8.00 9.50  8.00 10.0
0 
8.00 10.0
0 
8.00 
 75th 
Cen
tile 
14.0
0 
14.0
0 
12.0
0 
13.00 12.0
0 
 12.0
0 
14.0
0 
12.0
0 
12.0
0 
12.0
0 
Table 9:  The distribution of fetal heart rate and fetal heart rate variability at the 
different time intervals depending on the indication for the induction of labour.  
(Mean ± standard deviation). 
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INDICATION FOR INDUCTION OF LABOUR 
 Previous IUD Postterm pregnancy 
TIMING -10 0 10 20 30  -10 0 10 20 30 
Acceleratio
ns (per 10 
min) 
2(0;
4) 
2(1;
4) 
2(1;
4) 
2(0;
4) 
2(1;
4) 
 
1(0;
3) 
2(0;
4) 
2(0;
4) 
2(0;
3) 
2(1;
5) 
Early 
Deceleratio
ns (per 10 
min) 
0(0;
0) 
0(0;
0) 
0(0;
0) 
0(0;
0) 
0(0;
0) 
 0(0;
0) 
0(0;
0) 
0(0;
0) 
0(0;
0) 
0(0;
0) 
Variable 
Deceleratio
ns (per 10 
min) 
0(0;
1) 
0(0;
1) 
0(0;
1) 
0(0;
1) 
0(0;
1) 
 0(0;
1) 
0(0;
1) 
0(0;
1) 
0(0;
1) 
0(0;
1) 
Atypical 
Variable 
Deceleratio
ns (per 10 
min) 
0(0;
0) 
0(0;
0) 
0(0;
0) 
0(0;
0) 
0(0;
0) 
 0(0;
0) 
0(0;
0) 
0(0;
0) 
0(0;
0) 
0(0;
0) 
Late 
Deceleratio
ns  (per 10 
min) 
0(0;
0) 
0(0;
0) 
0(0;
0) 
0(0;
0) 
0(0;
0) 
 0(0;
0) 
0(0;
0) 
0(0;
0) 
0(0;
0) 
0(0;
0) 
 
Table 10:  The distribution of accelerations and decelerations of the fetal heart at the 
different time intervals depending on the indication for the induction of labour.  
(Median (25th centile;75th centile). 
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The number of recordings with at least one acceleration per recording in the group 
who had been induced for previous IUD was 76.8%.  The corresponding figure for 
the postterm group was 70.3%.  (p = 0.09).  The distribution in relation to the timing 
of the misoprostol is shown in figure 3. 
 
 
Figure 3:  The percentage of recordings with at least one acceleration per recording 
in relation to the timing since administration of misoprostol in the two study 
groups. 
 
The occurrence of reactive patterns (recordings with at least two accelerations) is 
illustrated in figure 4.  There were more reactive patterns at all time intervals after the 
administration of misoprostol (figure 4) but these differences did not quite reach 
statistical significance.  (Chi2 for linear trend; p = 0.09). 
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Figure 4:  The percentage of reactive patterns in each group related to the time of 
the administration of misoprostol. 
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DISCUSSION 
Prostaglandins are highly efficacious cervical ripening agents that are useful 
clinically as adjuvants to labour induction. Notwithstanding the beneficial use of 
these agents, they are however associated with potential for uterine hyperstimulation 
and fetal heart rate abnormalities. We did a retrospective study to determine the 
effect of 50mcg misoprostol given orally on fetal heart rate, fetal heart rate variability, 
accelerations and decelerations in the first 40 minutes after administration. We did 
not reassess the effect of misoprostol in subsequent doses. 
It was more difficult to assess the ten minute windows of the cardiotocographs 
(CTG‟s) than we anticipated. Determining fetal heart rate was often difficult over 
such a short period. The investigator could not compare the ten minute window with 
the two windows immediately prior to or immediately after index ten minutes because 
of the randomization process. We therefore determined the highest and lowest fetal 
heart rate, as well as the average fetal heart rate for each ten minute window. The 
eventual analyses were the same irrespective of which rates were used. 
 Assessment of the variability was also at times limited to only two minutes, 
especially when several accelerations were present. It was not difficult to calculate 
accelerations once the baseline was established. The classification of decelerations 
depended on the presence of decelerations and also whether they were recorded. 
Some decelerations classified as variable may have been late or early where 
possible contractions were not monitored. It is of interest to note that where 
abnormalities occurred in a single ten minute window, they invariably recovered in 
the following two ten minute window, as was observed after the randomization was 
unblinded. 
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We found no statistical significant difference of mean fetal heart rate and baseline 
variability in relation to time recordings after administrating of misoprostol (Table 9). 
There were no statistically significant differences in the distribution of accelerations 
and decelerations in different time intervals (table 8). 
Previous reports are consistent with the index study except that the vaginal route of 
lower dosing misoprostol regimen (defined as 25mcg or less at 4 hourly intervals) 
was used. These women were likely to experience uterine hyperstimulation, both 
with (RR 0.50, 95% CI 0.36-0.71) and without (RR 0.61, 95% CI 0.49-0.76) fetal 
heart changes, with trends towards fewer infants with Apgar scores of less than 
seven at five minutes (RR 0.76, 95% CI 0.40-1.45), and fewer neonatal intensive 
care unit admissions (RR 0.82, 95% CI 0.64-1.05). (34) 
There were more reactive patterns at all time intervals after the administration of 
misoprostol (figure 4) but these differences did not quite reach statistical 
significance. The percentage of reactive patterns, compared with the ten minute prior 
to the dosage was highest in the windows starting 10 and 20 minutes later 
respectively. This is in keeping with studies that concentrated on pharmacokinetic 
properties after oral and vaginal misoprostol administration. Following oral 
administration misoprostol is rapidly absorbed; the plasma level increases and peaks 
at about 30 minutes then declines by 120 minutes and remains low thereafter. 
(35)The mean onset of effect after oral route was 7.8 minutes, with maximal effect 
after a mean of 25.5 minutes. The mean onset of uterine activity was seen after 20.9 
minutes, with a maximal effect after 46.3 minutes. (35) 
In both study groups, no neonatal complications or neonatal intensive care 
admissions were reported (table 6). Serious side effects (e.g. fetal hypoxia) are 
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usually secondary to hyperstimulation of the uterus. The majority of studies which 
compare labour induction with misoprostol and dinoprostone or oxytocin show 
greater incidents of uterine hyperstimulation with misoprostol. However in studies 
using lower doses 50 mcg oral misoprostol 4 hourly or 25mcg vaginal misoprostol 4 
hourly, hyper stimulation rate are similar to those women induced with dinoprostone. 
(4). There were no cases of hyperstimulation as assessed by CTG‟s or as reported 
in the patient files. 
The mean birth weights were 3142.7g in the previous IUD group and 3092.4g in the 
post term groups in spite of significant difference in gestational age at birth. The 
reason for this difference is unclear. This difference is probably not of clinical 
importance, considering the good perinatal outcome in both groups. However, it may 
be that current clinical and other methods used to determine efficiency of placental 
function is not adequate. Even if this was the case, the lack of serious adverse 
outcomes is reassuring.  
In total from both groups, 16.5% delivered by caesarian section. Fetal distress 
occurred commonly in women with a history of previous IUD but this difference was 
not statistically significant (10% in the previous IUD group and 1.9 % in the post-term 
group). In the literature 44 trials included in meta-analysis provided data for 5735 
subjects who participated in trials that assessed the impact of misoprostol on 
caesarian section rate. In 26 of 44 trails (59.1%) caesarian section rate was lower for 
patients randomized to receive misoprostol. This data provides strong support for the 
conclusion that misoprostol reduces caesarean rate amongst women who undergo 
induction of labour compared to women receiving alternative induction agents (36).  
It will be impossible though to draw any conclusions from the index study as only one 
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induction agent (misoprostol) was used. Nonetheless the caesarean section rate was 
significantly lower than the rate of our service which is currently 41%. 
It was also of interest to note that as many as 14.1% of the total inductions were not 
justified as they were not necessarily repeatable causes (e.g. 13 chorioamnionitis, 4 
congenital abnormalities and 1 cord prolapse), see (Table 2). This affords us an 
opportunity to heighten awareness amongst colleagues about strict academic criteria 
that have to be followed before induction of labour, as this practice might lead to 
avoidable iatrogenic maternal and fetal morbidity. Complications would include 
uterine hyperstimulation, failed induction of labour and cord prolapse. (36). All of the 
above mentioned adverse outcomes would then ultimately lead to an increase in the 
caesarean section rate and there may be challenges in anterpartum and intrapartum 
care in subsequent pregnancies due to lower segment morbidly adherent placenta 
implantations. (37) 
The demographic data of the participants (Table 1) showed no statistical difference; 
however it would be interesting to assess the link between smoking, high BMI, 
previous or current diabetes and hypertension or preeclampsia with misoprostol use. 
The index study lacks statistical power to assess such parameters and therefore 
large prospective randomized control trials are still needed.  
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STRENGHTH AND WEAKNESSES OF THE INDEX STUDY  
The index study confirms the absence of fetal heart tracing abnormalities when using 
low dose (first 50mcg) oral misoprostol; however we do not know the effect that 
could be caused by administration of subsequent doses. It was also difficult to 
determine the study size because we were not comparing different methods of 
induction. This was for a period of eighteen months at Tygerberg Hospital in patients 
with normal umbilical artery Doppler studies and found to be safe from a practical 
point of view. However we do not know what would have happened to patients with 
compromised umbilical artery Doppler e.g. pre-eclampsia, more large prospective 
randomized control trials are still needed. 
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CONCLUSION 
1. In the absence of contra indications, 50mcg of oral misoprostol can be given to 
mothers for induction of labour as no harmful fetal heart tracing abnormalities 
were found for 45 minutes, however large prospective randomized control trials 
are still needed to confirm effectiveness and evaluate further maternal and 
neonatal safety issues. Optimal dose and frequency also still need robust 
interrogation. 
2. Based on this thesis it does appear that misoprostol is probably not harmful to 
the fetus when it is given in dosages of 50mcg orally. 
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